Slaying little dragons: the impact of the Guinea Worm Eradication Program on dracunculiasis disability averted from 1990 to 2016 by Cromwell, Elizabeth A. et al.
eCommons@AKU
Department of Paediatrics and Child Health Division of Woman and Child Health
June 2018
Slaying little dragons: the impact of the Guinea
Worm Eradication Program on dracunculiasis
disability averted from 1990 to 2016
Elizabeth A. Cromwell
Sharon Roy
Dieudonne P. Sankara
Adam Weiss
Jeffrey Stanaway
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr
Part of the Pediatrics Commons
Recommended Citation
Cromwell, E. A., Roy, S., Sankara, D. P., Weiss, A., Stanaway, J., Goldberg, E., Pigott, D. M., Larson, H., Vollset, S. E., Bhutta, Z. A.
(2018). Slaying little dragons: the impact of the Guinea Worm Eradication Program on dracunculiasis disability averted from 1990 to
2016. Gates Open Research, 2, 30.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/697
Authors
Elizabeth A. Cromwell, Sharon Roy, Dieudonne P. Sankara, Adam Weiss, Jeffrey Stanaway, Ellen Goldberg,
David M. Pigott, Heidi Larson, Stein Emil Vollset, and Zulfiqar Ahmed Bhutta
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/697
Gates Open Research
 
Open Peer Review
Discuss this article
 (0)Comments
RESEARCH ARTICLE
Slaying little dragons: the impact of the Guinea Worm
Eradication Program on dracunculiasis disability averted from
 1990 to 2016 [version 1; referees: 3 approved]
Elizabeth A. Cromwell ,       Sharon Roy , Dieudonne P. Sankara , Adam Weiss ,
       Jeffrey Stanaway , Ellen Goldberg , David M. Pigott , Heidi Larson ,
         Stein Emil Vollset , Kristopher Krohn , Kyle Foreman , Peter Hotez , Zulfiqar Bhutta ,
     Bayu Begashaw Bekele , Dumessa Edessa , Nicholas Kassembaum ,
   Ali Mokdad , Christopher J. L. Murray , Simon I. Hay 1,9
Institute for Health Metrics and Evaluation, University of Washington, Seattle, Seattle, WA, USA
Centers for Disease Controls and Prevention, Atlanta, GA, USA
World Health Organization, Geneva, Switzerland
The Carter Center, Atlanta, GA, USA
College of Medicine, Baylor University, Houston, TX, USA
Aga Khan University, Karachi, Pakistan
University of Gondar, Gondar, Ethiopia
Haramaya Univerisity, Dire Dawa, Ethiopia
Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
Abstract
 The objective of this study was to document the worldwideBackground:
decline of dracunculiasis (Guinea worm disease, GWD) burden, expressed as
disability-adjusted life years (DALYs), from 1990 to 2016, as estimated in the
Global Burden of Disease study 2016 (GBD 2016). While the annual number of
cases of GWD have been consistently reported by WHO since the 1990s, the
burden of disability due to GWD has not previously been quantified in GBD.
 The incidence of GWD was modeled for each endemic country usingMethods:
annual national case reports. A literature search was conducted to characterize
the presentation of GWD, translate the clinical symptoms into health sequelae,
and then assign an average duration to the infection. Prevalence measures by
sequelae were multiplied by disability weights to estimate DALYs.
 The total DALYs attributed to GWD across all endemic countriesResults:
(n=21) in 1990 was 50,725 (95% UI: 35,265–69,197) and decreased to 0.9
(95% UI: 0.5–1.4) in 2016. A cumulative total of 12,900 DALYs were attributable
to GWD from 1990 to 2016.
 Using 1990 estimates of burden propagated forward, thisConclusions:
analysis suggests that between 990,000 to 1.9 million DALYs have been
averted as a result of the eradication program over the past 27 years.
Keywords
Guinea Worm, dracunculiasis, disability adjusted life years, DALYs,
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Introduction
Dracunculiasis, also known as Guinea worm disease (GWD), 
is caused by the parasitic worm Dracunculus medinensis (liter-
ally, little dragon from Medina)1. The transmission cycle begins 
when Guinea worm larvae are released into common stagnant 
sources of surface drinking water (e.g., ponds, lakes, unprotected 
shallow wells) where they are consumed by minute aquatic 
crustaceans (copepods). In about two weeks, the larvae inside 
the copepods develop into the infective stage2. At this time, if 
contaminated water is ingested, larvae migrate through the intes-
tinal wall into the connective tissues, where they mature and 
mate. Approximately 10–14 months post-infection, a painful, 
burning blister is created on the skin. The skin over the blister 
sloughs-off in about 48 hours, revealing the skin lesion and the 
anterior end of the worm. To relieve the pain, infected persons 
immerse the affected body part in water, triggering the worm 
to emerge through the skin and expel her larvae and the cycle 
begins again2–5.
The subsequent ulcer is painful and can often become infected, 
but most individuals recover over a period of weeks to months. 
Permanent disability, as well as death, have been documented 
but are very rare6. There is no specific chemotherapy for GWD 
nor vaccine available. Diagnosis occurs at emergence2 and treat-
ment is limited to case management to avoid secondary bacterial 
infections. In the context of eradication programs, the tradi-
tional practice of wrapping the worm around a stick as it slowly 
emerges has been replaced by wrapping the worm around 
a sterile gauze and is augmented with wound management using 
sterile bandages, topical antibiotic ointment, and treatment with 
anti-inflammatories7.
The global campaign to eradicate Guinea worm began in 
1980 at the U.S. Centers for Disease Control and Prevention 
(CDC)1. The campaign gained momentum when Guinea worm 
eradication was proposed to measure the success of the International 
Drinking Water Supply and Sanitation Decade of 1981–19902,8. 
The global eradication effort is led by national governments and 
communities, with the support of a coalition of partners includ-
ing The Carter Center, WHO, CDC, UNICEF and other partners 
and donors8. To break the cycle of transmission, national Guinea 
Worm Eradication Programs implement case detection and 
containment, provision of safe water sources, distribution 
of filter cloths and pipe filters, water source treatment with 
a larvicide (temephos), and health education7.
In 1990, a total of approximately 624,000 cases were reported 
globally; in 2016, only 25 cases were reported across four 
remaining endemic countries9. If the global campaign is success-
ful, Guinea worm could be the second human disease in history 
eradicated by direct public health interventions10. The costly 
up-front investment in eradication is often cited as a mecha-
nism to avoid the repeated and ongoing costs of treatment and 
prevention11,12. Although there is no consensus on the ideal 
methodology to quantify the economic or social benefits of 
eradication13, the impact of eradication in terms of alleviating 
human suffering is clear12.
The first report of GWD surveillance was released in 198214 
and the World Health Assembly resolution WHA39.21 was 
endorsed in 1986. The annual number of cases of GWD has been 
consistently reported by WHO since the 1990s, but the burden 
of disability due to GWD has not previously been quantified 
in the Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD). Several village-level studies conducted between 
1970 and the mid-1990s have described the clinical presentation 
of GWD15, and have quantified economic and productivity losses 
due to temporary and long-term disability. Given the historic 
accomplishments of global eradication efforts1, as well as the 
impetus for continued investment, an estimate of the burden of 
GWD comparable to other diseases generated by the GBD 2016 
framework is valuable. Disability-adjusted life years (DALYs) 
serve as a measure of overall disease burden, expressed as the 
number of years lost due to disability or early death. DALYs 
estimated by GBD are comparable between countries and 
through time; for example, the burden of GWD can be compared 
not only to other infectious diseases but chronic conditions as 
well16. Further, comparison of estimates of burden from the early 
1990s could be used to construct alternative scenarios of the burden 
of GWD had the eradication program had not been implemented. 
Each disease eradication event (this may be only the second) 
provides important data on the economic case for eradication. 
Moreover, because simply documenting contemporary DALYs16 
can lead to the misplaced interpretation that the case for 
continued investment in a disease is diminished, measuring 
the benefits of eradication over the entire period of interven-
tion needs a longer-term perspective11,13,16. Here we estimate 
DALYs attributable to GWD between 1990 and 2016 as part of 
GBD 2016.
Methods
The Global Burden of Disease study
The burden of GWD was estimated for the first time in GBD 
201616. GBD produces the only comprehensive DALYs for 
333 diseases and injuries, from 1990 to the present, for 195 
countries and territories16. A detailed description of GBD 2016 
methodology is presented elsewhere17,18. Once the prevalence of 
a cause is estimated, data on severity and the occurrence of 
particular consequences of disease, or “sequelae,” are used to 
determine the proportion of prevalent cases experiencing each 
sequela. The sequelae are then matched to health states and 
assigned disability weights18. GBD causes are collectively 
exhaustive and mutually exclusive.
Data sources. We extracted annual country-level Guinea worm 
case data from the Weekly Epidemiological Record (WER), 
published by WHO, as detailed in Supplementary File 1. In the 
early 1990s, there are years for which annual case data are either 
missing or inconsistent with preceding/following annual reports. 
Thus, annual case data were reviewed for completeness and 
plausibility by comparison with each country’s longitudinal case 
data and implausible case reports were excluded (Supplementary 
File 1). For example, in the case of Niger, which reported 32,829 
cases in 1991 and then 500 in 1992, followed by 25,346 in 
1993, the 1992 case data were treated as an outlier. A 
literature search using the PubMed database identified peer-
reviewed publications (see Table 1) that described the clinical 
presentation of GWD in terms of symptoms, sequelae, and dura-
tion of morbidity among individuals with incident or prevalent 
GWD.
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Statistical analysis. The incidence of GWD was then modeled 
individually for each country considered endemic in 1990 using 
Stata (Release 13; StataCorp; College Station, TX). Incidence 
was modeled using either reported case data (where available and 
plausible; see Supplementary File 1) or using a Poisson regres-
sion over time, by country. For years and locations for which 
case data were reported and considered plausible, 1,000 draws 
estimating incidence were generated using a beta distribution 
of cases and annual national population minus cases to intro-
duce uncertainty, relying on the assumption that national Guinea 
Worm Eradication Program data reflect the annual case burden. As 
Guinea worm case data were assumed to represent incidence of 
new infections, we employed a Poisson regression per country to 
predict cases for years and locations for which case data were 
missing or excluded, with year as the predictor, and the national 
population as the offset. The predicted incidence and standard error 
from the Poisson model were then used to generate a ran-
dom distribution of 1,000 incidence draws for those years with 
missing or incomplete case data. For comparison, the analysis 
was repeated entirely without exclusion of possible implausible 
data.
Calculation of disability-adjusted life years (DALYs). To 
convert estimates of prevalence into quantifiable and comparable 
measures of disability, GBD first generates estimates of years 
lived with disability (YLDs), which for GWD are the product of 
prevalence and a disability weight for all sequelae, corrected for 
comorbidity. Disability weights are measured on a scale from 0 
to 1, with 0 implying a state that is equivalent to full health and 
1 a state equivalent to death. In order to generate an estimate of 
total DALYs from 1990 to 2016, cause-specific years lived with 
disability are summed with YLDs for each location and year.
For GWD, the following steps were taken to assign health states 
to sequelae. First, the results of the literature review of Guinea 
worm-related disability were used to identify sequelae related to 
Table 1. Summary of Guinea-worm-related disability data reported in peer-reviewed literature.
Countryref Year(s) Number of 
communities 
(sample size*)
Type of morbidity 
reported**
Mean duration Proportion 
affected
Nigeria19 1985 1 village 
(444 individuals)
Incapacitation 26 days 93.4%
Nigeria20 1986 1 village 
(325 individuals)
Incapacitation 60 days 63%
Nigeria21 1983–1984 295 households Pain 12.7 weeks
Incapacitation 4.2 weeks Severe: 58%
Nigeria22 1993 2 villages 
(982 individuals)
Incapacitation - 21%
Nigeria23 1971–1975 17 villages 
(sample size not 
reported)
Pain -- Severe: 12% 
Moderate: 31% 
Mild: 57%
Incapacitation 100 days --
Infection at wound site -- 9.8%
Musculoskeletal problems --
Nigeria15 1971–1974 47 villages 
(563 individuals)
Pain 4.2 weeks to  
7.2 weeks
--
Infection at wound site 10 weeks 17.4%
Musculoskeletal problems - 4.6%
Uganda24 1992 43 clusters 
(301 women surveyed)
Incapacitation 6 months 40%
Benin25 1987–1989 2 villages 
(30 households)
Incapacitation 39–59 days 
(across 2 sites)
--
Ghana6 1991 10 villages 
(195 individuals)
Pain 12–18 months 28.2%
Incapacitation -- 34%
Ghana26 1973 8 villages 
(20 men)
Incapacitation 2.4 to 5.3 weeks 90%
Infection at wound site -- 45%
*Sample size represents total number of individuals with Guinea worm disease (either prevalent or historical cases).
**The term “incapacitation” captures any reports of limited mobility or inability to perform daily tasks, as measurement of 
incapacitation was variable across studies. “Musculoskeletal problems” encompasses a wide range of complications affecting joints 
and tissues, arthritis, and complications due to infections that could affect the lower limb.
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Guinea worm emergence. For each sequela, an estimate of its 
duration (as a fraction of one year) was multiplied across the 
1,000 incidence draws to approximate prevalence. A simulation 
was run to adjust disability weights for comorbidities for all causes 
of the same sequelae across GBD18. For each sequela, the adjusted 
disability weights were multiplied by prevalence and summed to 
estimate DALYs for GWD by location and year for each draw. 
From the 1,000 draws we calculated the point estimate as the 
mean of the draws, and the 2.5th and 97.5th percentile draws used 
to construct 95% uncertainty intervals (UI) for the estimation 
years of 1990, 1995, 2000, 2005, 2010, and 2016, and then inter-
polated to create the entire 1990–2016 time series. The mean of 
these annual estimates were summed to produce a total number 
of DALYs attributable to GWD for 1990–2016.
To estimate the number of DALYs that could have occurred in the 
absence of eradication interventions four simple scenarios were 
explored. First, the estimate of total DALYs was extrapolated 
from 1990 to 2016 accounting for no other changes. Second, 
DALYs from 1990 were extrapolated according to the annual 
percentage change in country-level population growth using 
GBD population estimates. A third scenario assumed declines in 
DALYs occurred solely due to increased access to improved water 
sources using the GBD 2016 national water coverage covariate 
estimates from 1990–2016. In this scenario, the 1990 DALY esti-
mate was reduced on an annual basis according to the increase 
in the proportion of individuals with access to improved water 
sources. Finally, to account for burden in the 1980s that GBD 
results do not capture, the 1986 estimate of 3.5 million annual4 
cases was held constant (of which 3.3 million cases estimated 
for Africa27) and multiplied by the mean DALY per case from 
GBD. The total number of DALYs predicted via GBD 2016 were 
then subtracted from the total produced under each alternative 
scenario to estimate the number of DALYs averted due to the 
eradication campaign. For the 1986–2016 comparison, the 
burden of GWD was assumed to decline 20% annually from 
1987–1989 as case data from this period are limited and not 
nationally representative for most locations.
Results
Summary of data sources
A total of 21 countries were considered Guinea worm-endemic 
as of 1990 (Figure 1)28. Sudan and South Sudan were modelled 
separately in GBD for the entire time series even though they 
were one country until 2011. A total of 729 country-year-specific 
data points were identified (Supplementary File 1). The literature 
review identified ten papers in which Guinea-worm-related mor-
bidity was reported, summarized in Table 1. Sequelae associated 
with GWD relate to the process of the worm’s emergence: pain 
and itch as the worm exits the body, and the subsequent wound 
that requires several weeks to heal and which can be further 
complicated by abscesses and chronic ulcerations, joint and tissue 
damage, as well as secondary infection in connective tissues29. 
Pain and itch were widely reported during the worm’s emergence; 
these persist for approximately one month until the worm exits the 
body2. Several studies20,23,24,30,31 found that worms predominantly 
emerge from the lower limbs, with reports ranging from 98%22 
to 88%15 of all cases.
We assumed that every case of GWD, using GBD health state 
terminology, experienced “pain and disfigurement (moderate),” 
and “musculoskeletal problems, lower limb (moderate)” for 
a period of one month, followed by two months of “pain and dis-
figurement (mild).” Based on evidence from a study of long-term 
disability conducted in Ghana6, we then assumed that 30% of all 
case-patients then experienced “pain and disfigurement (mild)” for 
an additional nine months (approximately a total year of disabil-
ity) to account for longer-term disability associated with recovery. 
The disability weights32 associated with these sequelae are as 
follows: moderate disfigurement (with itch/pain), 0.188, 95% UI: 
0.125–0.267; musculoskeletal problems, lower limbs (moder-
ate), 0.079, 95% UI: 0.054–0.11; and mild disfigurement (with 
itch/pain), 0.027, 95% UI: 0.015–0.042.
Results of national-level GWD incidence estimates
Table 2 presents the total number of reported cases, modeled 
cases, total DALYs, and DALYs per capita for 1990, as well as 
the total country-specific DALYs for 2016 for comparison 
(individual country models are presented in Supplementary 
File 1). Overall, the GBD model predicts a total of approximately 
1.6 million cases of GWD in 1990 and 27 cases in 2016 (com-
pared to 25 cases reported in 2016). A total of 13 countries were 
missing case reports for at least one year, and a total of 
18 country-years of data were considered implausible (see 
Supplementary File 1), accounting for the large difference in 
reported and modeled case burden, particularly in 1990 and 
1995. Had these possible outliers not been excluded, the model 
would have predicted approximately 1.1 million cases of GWD 
for 1990.
DALY estimates
The total DALYs attributed to GWD across all endemic coun-
tries in 1990 was 50,725 (95% UI: 35,300–69,200). From 
1995 onward, the DALYs attributable to GWD dropped precipi-
tously, with 1995 DALY estimates of 4,020 (95% UI: 2,750–5,530), 
consistent with the expansion of eradication efforts in Africa 
throughout the mid-1990s and 2000s. In 1990, the majority of the 
DALYs occurred in Uganda (20,700; 95% UI: 14,300–28,200), 
Nigeria (12,100; 95% UI: 8,300–16,600), and what is now South 
Sudan (6,940; 95% UI: 4,810–9,390). In terms of DALYs per 
100,000, estimates in 1990 were the highest in Uganda (118; 
95% UI: 82–161), South Sudan (115; 95% UI: 80–156), and 
Ghana (26; 95% UI: 18–36)). For comparison against other causes, 
the 1990 DALY estimates per 100,000 indicate relative burden. 
For example, in Ghana, the 1990 DALY estimate for lymphatic 
filariasis was 80 (95% UI: 40-135) and schistosomiasis was 
276 (95% UI: 182—435). In Nigeria, the DALYs for lymphatic 
filariasis and schistosomiasis in 1990 were 208 (95% UI: 95—
377) and 301 (185—491), respectively (see GHDx search tool to 
search results by country and year).
By interpolating the quinquennial DALY estimates, the total 
cumulative DALYs due to GWD from 1990 to 2016 was approx-
imately 129,355 (sum of the mean model prediction). In the 
first scenario we tested in which the estimate of total DALYs 
from 1990 (50,725.4 DALYs per year) is held constant through 
2016, a cumulative 1.37 million DALYs could have occurred in 
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Figure 1. Distribution of Guinea worm disease: 1990, 1995, 2000, 2005, 2010, and 2016. Distribution of GWD cases for 1990, 1995, 2000, 
2005, 2010, and 2016. In dark grey, countries with ongoing transmission but no report; in light grey, countries never considered endemic; and 
in shades of red total annual case counts, including countries with interruption of transmission that had imported cases.
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Table 2. Country-specific burden estimates, comparing 1990 to 2016.
1990 2016
Country
Reported 
Cases
Predicted 
Cases†
Total DALYs DALYs per capita
DALYs 
Total
Point 
Estimate Lower UI Upper UI
Point 
Estimate
Lower 
UI
Upper 
UI
Benin 37,414 37,410.5 1,139.6 783.8 1,563.8 23.2 15.9 31.8 -
Burkina Faso 42,187 42,190.1 1,277.2 874.9 1,753.4 14.6 9.9 20.0 -
Cameroon 742 742.1 24.2 16.0 34.0 0.2 0.1 0.3 -
Central 
African 
Republic
* 188.5 6.2 3.4 10.1 0.2 0.1 0.3 -
Chad * 4,912.1 151.2 101.6 215.2 2.6 1.7 3.7 0.5
Côte d’Ivoire 1,360 21,323.4 652.2 436.8 897.3 5.4 3.6 7.5 -
Ethiopia 2,333 2,332.7 76.1 51.5 106.4 0.2 0.1 0.2 0.09
Ghana 123,793 123,810.0 3,804.7 2,616.5 5,210.4 26.0 18.0 35.7 -
India 4,798 4,800.3 156.4 105.9 217.9 0.02 0.01 0.03 -
Kenya 6 61.4 2.0 1.2 3.1 0.01 0.01 0.01 -
Mali 884 21,723.36 660.0 454.2 906.1 7.8 5.4 10.1 0.0
Mauritania 8,036 8,034.3 246.2 167.4 339.0 12.5 8.5 17.2 -
Niger * 61,698.8 1,896.3 1,280.2 2,618.4 24.3 16.4 33.6
Nigeria 394,082 394,078.7 12,067.6 8,345.6 16,593.6 12.8 8.9 17.7 -
Pakistan 160 160.1 5.2 3.4 7.5 0.004 0.003 0.01 -
Senegal 38 2,987.8 96.0 64.6 133.9 1.3 0.9 1.8 -
South 
Sudan**
* 229,724.3 6,939.9 4,811.8 9,394.0 115.1 79.8 155.8 0.2
Sudan * 8,116.9 260.7 174.1 363.8 1.4 1.0 1.9 -
Togo 3,042 16,659.15 510.2 344.7 704.5 13.7 9.2 18.9 -
Uganda 4,704 678,265.5 20,656.7 14,294.5 28,233.3 117.7 82.5 160.9 -
Yemen * 2,562.8 82.1 43.2 141.1 0.7 0.4 1.2 -
Total 623,579 1,661,782.7 50,725.4 35,265.3 69,197.0 - - - 0.9 
DALYs - Disability-adjusted life years
†Mean prediction from 1,000 draws.
*No data reported for 1990.
**South Sudan: Data for Sudan and South Sudan were disaggregated according to current national boundaries for the entire period 1990–2016 as 
GBD estimates are generated for current political boundaries. We acknowledge that pre-2011, Sudan and South Sudan were not separate countries 
and that pre-2006 Guinea worm eradication was implemented as a single national program33. 
the absence of any change in GWD incidence. In the second sce-
nario in which the 1990 DALY estimate is extrapolated according 
to annual population growth, approximately 2 million DALYs 
could have occurred. Third, accounting for secular improvements 
in improved water source access we predict a total of 1.1 million 
DALYs. Using these three scenarios, the number of DALYs averted 
by the Guinea worm eradication campaign may be as low as 
990,000 or as high as 1.89 million (see Table 3). Finally, by mul-
tiplying the mean DALYs per case generated by GBD (approxi-
mately 0.03) by the 1986 global case estimate of 3.5 million4, 
we project a total of 106,836 DALYs per year for a total of 3.3 
million DALYs that could have occurred from 1986–2016 
had the 1986 burden remained constant. In this scenario, we 
calculated 444,736 DALYs occurred under the eradication cam-
paign, allowing for annual case reductions of 20% from 1987–1989 
and GBD 2016 results for the period 1990–2016, resulting in 
approximately 2.8 million DALYs averted from 1986–2016.
Discussion
This study summarizes the first model of GWD included in 
the GBD study, estimating the burden of disease attributable to 
Guinea worm from 1990 to 2016. In comparison to GBD results, 
previously published studies present similar estimates of case bur-
den, particularly for the early 1990s. The first model published 
focused on incidence27 using reported case data corrected for 
underreporting, estimating approximately 3.3 million incident cases 
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Table 3. Global Guinea worm disease disability-adjusted 
life years (DALYs) averted comparing observed and 
alternative scenarios.
Inputs DALYs
Estimated cases* 1,661,783
DALYs 1990* 50,725
DALYs observed 1990–2016* 129,355
Annual 1990 burden remains constant 1,369,586
Increases with population growth 2,014,473
Changes in proportion with safe water coverage 1,119,703
DALYs averted: constant burden 1,240,231
DALYs averted: increases with population 1,885,118
DALYs averted: changes in safe water 990,348
*Using Global Burden of Disease 2016 results.
of GWD in Africa occurred in 1986 across 19 countries (Sudan 
and South Sudan modeled as one country); including India and 
Pakistan the estimate is 3.5 million cases for 19864. Another anal-
ysis, conducted in collaboration with the World Bank, estimated 
approximately 1.5 million cases in 199034, a number similar 
to the 1990 results herein. Other studies have presented the contri-
bution of Guinea worm eradication in the context of Millennium 
Development Goals35 and economic productivity gains34, and a 
recent economic analysis calculates DALYs averted per dollar 
as a metric to justify economic investment in eradication versus 
control36. Here we similarly focus on DALYs averted as esti-
mated by GBD 2016, with country-level DALYs presented for the 
first time.
Whether disease eradication is motivated by an economic 
and/or moral imperative, there are challenges inherent in quanti-
fying the benefits attained. The DALY is a metric that enables 
decision-makers and public health officials to compare across 
different causes based on the disease experience, not only the 
decline in cases. Our analysis includes a review of the scientific 
literature on GWD, which is sparse and largely published before 
1990. These studies may not be representative of the morbidity 
experienced during the eradication campaign as case management 
interventions reached scale. Since we also did not account for the 
quantity of worm burden per case, our current DALY estimates 
may underestimate the true burden of GWD, as evidence sug-
gests severity of disability is related to the number of worms23. 
Secondary complications associated with worm emergence that 
persisted beyond a year post-emergence were not included, as 
data on the long-term clinical outcomes of GWD were scarce. 
Assumptions used in other analyses are based on single studies 
with very small numbers36. For example, the estimate of 0.5%6 
of all cases resulting in permanent disability results from a report 
of one individual with permanent damage to a joint post worm 
emergence from a sample of 195 individuals. Given the intensity 
of community-based surveillance over the course of the eradica-
tion campaign, it might be possible to generate better param-
eters for GWD sequelae if detailed case data could be made 
available.
Our analysis is the first to quantify the DALY burden of GWD 
in the GBD 2016 framework and is subject to all GBD 2016- 
specific limitations16–18,37. First, due to the scope of GBD, we were 
only able to analyze from 1990 onward. It is plausible that case 
data in the early 1990s do not capture the true incidence of GWD 
in Africa due to under-reporting as many national eradication 
programs had not reached full geographic coverage of endemic 
areas. In terms of historical burden, this analysis also does not 
account for the cases that were reported prior to 1990 from India 
and Pakistan, countries which had begun eradication efforts in 
1980 and 198738, respectively, much earlier than most of the other 
countries (see SI for summary of national case searches). Had 
our analysis accounted for a larger proportion of the historical 
burden the number of DALYs averted by eradication campaign 
interventions would be greater. Second, we attempted to correct 
for under-reporting by omitting implausible annual country reports 
which also could have introduced bias into the 1990 estimate. 
Nevertheless, to ignore missing or implausible data points would 
have otherwise introduced clear downward bias in our DALY 
estimates, understating the true burden during this period. Prior 
evidence acknowledges incomplete reporting39, and our analy-
sis introduced greater levels of uncertainty for years in which 
case estimates were missing or considered implausible. If 
data points that were considered outliers had not been excluded 
from the analysis, the total number of estimated cases would be 
1.1 million, still far greater than the 623,579 cases reported by 
WHO in 1990. This increase would account for missing case 
data from Central African Republic, Chad, Niger, South Sudan, 
Sudan and Yemen. Further, reliance on nationally representative 
data did not enable us to account for the subnational distribu-
tion of disease, which may have resulted in over-prediction for 
country-years that were missing data, notably for Uganda and 
South Sudan.
Our model suggests that approximately 129,000 DALYs were 
attributable to GWD for the entire period 1990–2016. As India 
and Pakistan began national eradication efforts much earlier, 
this burden largely occurred in Africa, with approximately 50,000 
DALYs estimated in 1990 alone. A simple extrapolation of the 
1990 mean DALY estimate would imply that 1.3 million DALYs 
could have occurred in the absence of the eradication program 
from 1990 onward. Accounting for population growth, that esti-
mate grows to 2.0 million. Using only national level measures of 
safe water quality to account for secular improvements that could 
have eliminated transmission, this would suggest that approxi-
mately 990,000 DALYs have been averted over the past 27 years. 
Although data availability pre-1990 limit our ability to con-
struct complex alternative scenarios, the reduction in GWD case 
reports outpaced national-level measures of water quality. There 
was approximately an 80% reduction in reported cases of GWD 
from 1990 to 1995, whereas the change in water access at the 
national level (a GBD covariate) during this period ranged from 
a decrease of 2% in coverage (Pakistan) to an increase of 23% 
(Sudan), suggesting the eradication campaign interventions 
such as filter cloths, health education and case containment 
account for a large proportion of the reduction in burden.
While these alternative scenarios present simple estimates of 
the possible GWD-related disability that has been prevented 
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since 1990, future analyses with more detailed national-level 
data could generate better estimates. It is likely our estimates of 
DALYs averted under-estimate the true impact of eradication 
as interventions in other high-burden settings like Ghana and 
Nigeria were already underway. These estimates also do not 
capture declines in GWD incidence occurring in India40 and 
Pakistan41 in the 1980s, which combined reported between 
20,000-30,000 cases per year combined. Using the 1986 esti-
mate of 3.5 million cases4 would double the burden of GWD that 
we estimated for 1990 and result in approximately 2.8 million 
DALYs averted (assuming 1986 burden held constant) from 
1986–2016.
The future of Guinea worm eradication will depend on a number 
of factors, including elimination of infection in animals, sur-
veillance in settings with insecurity, and maintenance of a pro-
grammatic infrastructure prior to elimination of transmission42. 
Critics of eradication programs may claim that the “cost per 
case” to sustain interventions at this late stage could be better 
allocated to more pressing public health priorities. Nonetheless, 
a recent economic analysis shows that eradication is still effec-
tive even at this late stage36. Should eradication efforts continue, 
the small number of cases reported will not change the overall 
results of historical DALYs estimated in this study, even if eradi-
cation takes decades. The costs expended versus DALYs saved 
calculations will look increasingly disproportionate as annual 
case totals continue to decline. By quantifying the contribution 
of the global eradication program in terms of DALYs averted, we 
demonstrate the huge benefit in the reduction of human 
suffering. This study is important as it facilitates a more holis-
tic assessment of the entire achievement of the campaign while 
the final stubborn cases are eliminated.
Disclaimer
The findings and conclusions in this report are those of the 
authors and do not necessarily represent the official position 
of the Centers for Disease Control and Prevention.
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picture of the GW situation in most of the endemic countries since there was a village-based surveillance
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that the reduction was mainly achieved due to improved reporting as a result of instituting trained village
based volunteers and thereby establishing effective village based surveillance system with robust
supervisory network from national level all the way down to district or county or LGA levels as the case
may be in each endemic country.  Overall, I am appreciative of the work done by the authors.  I have seen
firsthand the immense suffering and terrible consequences of this crippling disease and it is indeed worth
publishing this work to celebrate the great breakthrough attained in eradicating this dreadful disease.
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Author Response 24 Jul 2018
, Simon Hay
Thank you for the comments. We agree with the reviewer that reductions in cases post from 1990
to 1995 may reflect changes in reporting procedures.  The results do include larger uncertainty
intervals for the 1990 estimates compared to later time points, largely driven by the model
attempting to correct for under-reporting or missing data from the early 1990s. 
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